The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates

QJM: An International Journal of Medicine

Volumn 102, Issue 1, 2009, Pages 35-42

  Rietbrock, S ^a   Olson, M ^b   van Staa, T P ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; SIMULATION; UNITED KINGDOM;

EID: 58149099014     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn130     Document Type: Article

References (18)

1. Cooper C, Campion G, Melton LJ. Hip fracture in the elderly: A worldwide projection. Osteoporos, Int 1992; 2:285-9.
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group.Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23:570-8.
3. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18:1023-31.
4. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, et al. Non-compliance: The Achilles' heel of anti-fracture efficacy. Osteoporos Int 2007; 18:711-9.
5. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15:1003-8.
6. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: A database analysis study. Curr Med Res Opin 2006; 22: 1757-64.
7. Cooper C. Beyond daily dosing: Clinical experience. Bone 2006; 380(4 Suppl. 1):S13-17.
8. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-9.
9. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al HORIZON pivotal fracture trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-22.
10. Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350:1097-9.
11. Stevenson M, Lloyd Jones M, de Nigris E, Brewer N, Oakley J. The clinical effectiveness and cost-effectiveness of prevention and treatment of osteoporosis. National Institute for Clinical Excellence, December 2003. [http://www.nice.org/page.aspx?o=115573] Accessed 10 May 2004.
12. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 1998; 339:380-6.
13. Melton LJ3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA. Melton weighing fractures. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003; 14:383-8.
14. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 2002; 288:2868-79.
15. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013-22.
16. van Staa TP, Wegman S, de Vries F, Leufkens HGM, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285:1850-5.
17. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000.
18. van Staa TP, Dennison EM, Leufkens HGM, Cooper C. The epidemiology of fractures in England and Wales. Bone 2001; 29:517-22.